SERA
- Sera Prognostics, Inc.
()
Overview
Company Summary
Sera Prognostics, Inc. (SERA) is a biotechnology company that specializes in developing innovative maternal and prenatal health diagnostics. The company's primary focus is to improve pregnancy outcomes by providing healthcare professionals with reliable, evidence-based information about a woman's individualized risk of preterm birth and other pregnancy complications.
SERA has developed a proprietary proteomic technology platform known as the PreTRM� test. This blood-based test is designed to assess a woman's risk of spontaneous preterm birth, which is defined as giving birth before 37 weeks of gestation. Preterm birth is a significant health concern for both the mother and the baby, and it can lead to various complications and long-term health problems.
By analyzing specific proteins found in a pregnant woman's blood, the PreTRM� test can identify biomarkers that have been associated with an increased risk of preterm birth. The results of the test provide healthcare professionals with valuable information that can guide clinical decision-making, leading to personalized care plans and interventions to mitigate the risk of preterm birth.
SERA's mission is to empower women and their healthcare providers with actionable insights to identify and manage the risk of preterm birth. By offering this advanced diagnostic tool, they aim to improve pregnancy outcomes, reduce healthcare costs, and enhance overall maternal and fetal health.
In addition to their focus on preterm birth, SERA is also actively involved in research and development initiatives to expand their product portfolio and address other pregnancy-related complications. Their goal is to advance the field of maternal-fetal medicine and contribute to the overall improvement of women's health during pregnancy.